INTRODUCTION
In recent years, end stage liver disease has become a major cause of morbidity and mortality in patients chronically infected with the Human Immunodeficiency Virus (HIV) who are coinfected with hepatitis C (HCV) or B virus (HBV) ( ). This trend may be explained [1] [2] [3] [4] by a prolonged exposure to viral hepatitis, because most patients were infected with HCV in the 1980s. This time interval is compatible with the occurrence of cirrhosis and its late complications, as accelerated fibrosis and cirrhosis are observed in more HCV-HIV coinfected patients compared to HCV mono-infected patients ( , ). 5 6 In parallel, thanks to the widespread use of combination antiretroviral therapy (cART) in industrialised countries, the incidence of Acquired Immune Deficiency Syndrome (AIDS) morbidity and related mortality has dramatically decreased, resulting in an increased life expectancy. However, this has also meant that the causes of death have shifted to predominantly non AIDS-related diseases, with a high proportion of end-stage liver diseases being observed ( , ). These major hepatic complications have emerged in the context of 2 7-10 excessive alcohol use metabolic issues such as steatosis ( ) and portal hypertension ( ) may also be related to antiretroviral treatment - 11 12 toxicity but their role in liver mortality remains to be defined.
On the other hand, treatments for viral hepatitis are now widely available in industrialised countries and viral eradication is achieved in 25 to 40 of HCV-HIV coinfected patients treated with a peginterferon and ribavirin combination ( ), while anti-HBV treatment is a %
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part of cART. However, the best treatment strategy for HCV in patients with an indication for cART remains controversial.
Several studies including the French national survey, Mortalit 2000 , have shown that complications of HCV and HBV are the " é "
second most frequent underlying cause of death after AIDS in HIV-infected patients, accounting for around 10 of deaths ( ).
One of the aims of the Mortalit 2005 survey, was to identify and describe the characteristics of HIV-infected patients who died from
end-stage liver disease. These patients were then compared to the population identified in 2000.
METHODS

Data collection
All hospital wards and networks known to be involved in the management of HIV infection in France were contacted and invited to participate in the Mortalit 2005 survey; this included those that participated in the Mortalit 2000 survey and physicians involved in
penitentiary medicine. Moreover, French societies of intensive care, pneumology and hepatology specialists were contacted and they asked their members to participate ( ). 17
Physicians prospectively reported deaths in HIV-infected adults (18 years or older) every three months in 2005, together with a short abstract describing the potential cause of death. Each case was then documented using a standardized questionnaire that collected information on the potential contributing causes of death, diseases present at time of death and included a global assessment of the underlying cause of death. One physician was especially dedicated to the survey in the coordinating team and oversaw harmonization of data collection. Duplicate reports were identified by cross-matching dates of birth and death. In addition, all participating wards estimated the number of HIV-infected patients seen at least once in 2004 in order to approximate the coverage of the survey.
In the present study, we analysed only those deaths with a known status for HCV and HBV. HCV infection was defined as the presence of serum HCV-antibody or HCV-ribonucleic acid (RNA), HBV infection by that of serum hepatitis B surface antigen or HBV-deoxyribonucleic acid (DNA), and hepatitis delta virus (HDV) infection by that of serum HDV-antibody. An excessive alcohol consumption was defined as daily alcohol intake higher than 50 grams and/or five glasses, and poor socio-economic conditions were defined as the patients having no health insurance, no employment, no accommodation, income below 535 per month and/or immigrant € in illegal situation.
Determination of the underlying cause of death
Information contained in the questionnaire was used to determine the underlying cause of death according to the International Classification of Diseases, tenth revision (ICD-10) rules: the underlying cause of death was the disease or injury, which initiated the train of morbid events leading to death ( ). The algorithm of determination was adapted to specific concerns in HIV infection ( ) and allowed 1 3 categorization of deaths as follow: AIDS-related causes according to the 1993 Centers for Disease Control (CDC) clinical classification ( ); liver disease including infection with HCV and/or HBV as well as hepatocellular carcinoma, cancers attributable neither to AIDS nor 18 to HCV/HBV infection, cardiovascular diseases, or other causes.
The underlying cause of death was classified as liver disease if the patient died from cirrhosis (ie, ascites, variceal bleeding, encephalopathy, spontaneous bacterial peritonitis, hepatocellular insufficiency), hepatocellular carcinoma or fulminant hepatitis, regardless of the potential relationship to HCV or HBV infection, alcohol or another cause. Patients with hepatocellular carcinoma who died from liver failure were classified as dying from hepatocellular carcinoma, to remain consistent with the definition of an underlying cause of death according to the ICD-10 classification.
Statistical analysis
We compared a) the underlying cause of death categorized in five categories (AIDS, liver disease including viral hepatitis, non-hepatitis and non-AIDS related cancer, cardiovascular disease, other cause) between 2005 and 2000; b) the characteristics of patients who died from a liver-related cause another cause, in 2005. versus 3 9 Among HIV-infected individuals with a liver-related cause of death, we compared the distribution of the following variables between 2000 and 2005: a) characteristics of cases; b) type of hepatic events leading to death; c) the proportion of HCV, HBV/HCV co-infections, and excessive alcohol consumption.
Between-group comparisons were performed using Chi-2 and Fisher tests for categorical variables, and the Kruskal-Wallis test for quantitative variables, using 0.05. A logistic regression model was used to compare characteristics of deaths from liver-related diseases α= to other deaths and included: age at time of death, gender, viral infection (HBV alone, HCV alone, both, no HBV or HCV infection), latest CD4 cell count < 200/mm3, CDC stage C and excessive alcohol consumption.
Statistical Analysis System (SAS) software version 9.1.3 was used for all analyses. Table 1 Amongst the deaths that occurred in 2005, most were men in their forties with more a known duration of HIV infection of >10 years ( ). Forty-four percent of patients who died were coinfected with at least one hepatitis virus, predominantly HCV. Table 1 In cases with known hepatitis status, the relative proportion of the five main underlying causes of death changed significantly between 2005 and 2000 (p <0.0001): the percentage of AIDS-defining illness decreased, whereas the proportion of liver-related causes of death and non-hepatitis and non-AIDS related cancers increased (
RESULTS
The
). HCV and HBV as causes of death represented 10.9 and 1.8 of deaths, Figure 1 % % respectively. Underlying causes of deaths did not differ between patients with known and unknown hepatitis status (p 0.52).
=
Characteristics of cases dying from liver-related diseases ( , ) Table 1 Table 2 In 2005, 138 liver-related deaths were notified. Excessive alcohol consumption was significantly more frequent among those dying from liver-related causes than in those dying from other causes ( ). Excessive alcohol consumption was more frequent among HCV Table 1 and HCV/HBV co-infected cases (47 and 83 , respectively) than among HBV co-infected cases (36 ) (p 0.03). Compared with
patients dying from other causes in 2005, patients dying from liver-related causes were significantly older, were more frequently infected by HCV or HBV, and were more likely to be excessive alcohol consumers (using logistic regression). The group dying liver-related deaths had progressed to AIDS less frequently than the group dying from other causes, but did not differ in CD4 count at time of death.
In 2005, the median age of patients at the time of death from liver-related causes was higher than the median age of those dying from liver-related causes in 2000 ( ). Furthermore, the time between diagnosis of HIV and death from liver-related diseases was longer in Table 2 2005 than in 2000 ( ). Amongst these liver-related deaths, virological suppression was greater in 2005 than in 2000, whereas the Table 2 slightly higher median value of the latest CD4 cell count in 2005 was not significantly different to the value in 2000 ( ). Table 2 Hepatic disease leading to death HBV-infected (11 ), while excessive alcohol consumption alone was reported in a single case ( ).
% Figure 2 Respective part of HCV, HBV, alcohol and other causes among liver-related deaths ( ) Table 3 In 2005, 138 liver-related deaths were notified 110 in 2000. Most of them were attributed to HCV infection in both 2005 and versus 2000, and less frequently to HBV infection, a dual HCV and HBV co-infection, an excessive alcohol consumption, or another cause. 4 9 In events were: decompensated cirrhosis in 70 cases; and other causes in 3 cases including two interferon-related lethal events (as described below).
HCV infection
2005, 98 patients died from HCV-related liver disease. These patients had a median age of 47 years and a median duration of 14.6 years since HIV diagnosis. The patients died in a state of moderate immunosuppression: median CD4 level at 231/mm ( 168 3 versus CD4/mm in 2000) and HIV-RNA <500 copies/ml in 62 of cases. HCV genotype was available in 70 cases: genotype 1 or 4 (n 47, 67
HBV infection
In 2005, 16 liver-related deaths were HBV-infected, were a median of 43 years old, and the median duration since HIV diagnosis was 15.4 years. Thirty-six percent of these patients were excessive alcohol consumers. All patients that were HBV-infected when they died received antiretroviral treatment and they died in a state of moderate immunosuppression: median CD4 level at 235/mm , and HIV-RNA 3 <500 copies/ml in 8 cases (50 ).
%
The proportion of patients that died from hepatocellular carcinoma among those that were HBV-infected at the time of death was 54% (7/13 cases) in 2000 38 (6/16 patients) in 2005. Other lethal hepatic events were attributed to decompensated cirrhosis in 9 cases, versus % and to the consequence of HBV reactivation in 1 case.
HBV/HCV co-infection
In 2005, 7 cases died from HBV/HCV-related liver diseases; the hepatic event leading to death was decompensated cirrhosis in 4 cases, and hepatocellular carcinoma in 3 cases (
2/16 cases in 2000). versus
Alcohol
In 2005, 9 cases died from an isolated alcohol-related liver disease ( 12 in 2000) . The hepatic events leading to death were versus decompensated cirrhosis in 6 cases, a hepatocellular carcinoma in 1 case, and undetermined causes in 2 cases. However, excessive alcohol consumption was notified in 63 of the 138 cases who died from a liver-related causes in 2005.
Contributing role of treatments in liver-related deaths
Amongst 138 cases who died from liver disease in 2005, some form of treatment was involved in 9 cases (7 ): antiretroviral treatment We believe that these results may not be explained by the fact that the wards targeted in 2005 slightly differed from those targeted in 2000, since the proportion of liver-related deaths and patients characteristics did not differ between wards that participated in both the from hepatocellular carcinoma, that can be extended to duration since HCV diagnosis, was significantly longer than in patients who died from non-liver-related causes (median: 15.8 years versus 10.8 years). Apart from HCV infection, known risk factors for hepatocellular carcinoma include male gender, age older than 60 years, HBV infection, excessive alcohol consumption, tobacco, diabetes, and high body mass index ( ). Some of these co-morbidities were frequent in our series of HIV-infected patients dying with hepatocellular 19-22 carcinoma, like HCV infection (69 ), chronic HBV co-infection (17 ), excessive alcohol consumption (41 ), and tobacco use (60 ).
The important role of hepatocellular carcinoma in HCV infected patients may be related to a high rate of treatment failure, especially since genotypes 1 and 4 represented 67 of HCV liver deaths in our study, and efficacy of pegylated interferon and ribavirin combination is % known not to exceed 15 in patients with such genotypes ( ).
%
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Conversely, the proportion and the number of HBV-related deaths remained low and stable between 2000 and 2005 and the rate of hepatocellular carcinoma as a cause of death among HBV-infected patients did not increase (7/13 cases in 2000 6/16 cases in 2005). versus Moreover, there was probably an underestimated proportion of delta co-infection in HBV-infected patients (two cases documented among six hepatocellular carcinoma related to HBV infection in 2005). As it is now well known in HBV mono-infected patients, HBV-DNA levels are directly correlated to the incidence of long-term complications of cirrhosis, hepatocellular carcinoma and deaths. In HBV-HIV co-infected patients, anti-HBV active cART makes it possible to achieve suppression of HBV replication and anti-hepatitis B early antigen seroconversion in a substantial proportion of patients particularly those who have a complete HIV suppression and a satisfactory immune recovery ( ). Lamivudine has been widely available since 1996, and if there was a beneficial impact of this therapy then this would have 23
been observed before 2000. The design of our study, therefore, did not allow for exploration of the effect of lamivudine. The widespread use of tenofovir, one of the most promising drugs against HBV in these patients, may rather explain this favourable evolution. Moreover, in cirrhotic patients with long-term suppression of HBV replication under tenofovir treatment, improvement in hepatic functions has been observed, creating hope for a potential reversal of end-stage liver disease, and for a survival benefit in this population ( , ). 24 25 Our study has also pointed out the emergence of new, albeit rare, causes of liver disease leading to death. Among them, cART was directly or indirectly associated in three cases including one case of didanosine-associated lactic acidosis in a patient with pre-existing cirrhosis, and two cases of portal hypertension. Although cART has significantly improved the prognosis of HIV infection, long-term complications of these drugs are increasingly recognized as significant causes of morbidity and mortality. Non-alcohol related fatty liver disease, which can evolve into non-alcohol related steatohepatitis, cirrhosis and ultimately hepatic failure, has been recently described as a complication due to multiple factors that co-exist in HIV-infected patients including metabolic abnormalities, chronic inflammation, concurrent infection with HCV ( ). Among them, stavudine and didanosine have proven to be commonly implicated in the occurrence of 12 mitochondrial abnormalities and of lactic acidosis.
More recently, some cases of non-cirrhotic portal hypertension have been described in HIV-infected patients (
). In such cases, 26-29 liver biopsy usually showed vascular lesions presenting as nodular regenerative hyperplasia. Patients underwent the significant complications of portal hypertension, such as variceal bleeding and refractory ascites. It has been hypothesised that these lesions were related to either exposure to didanosine ( ) intrahepatic microthrombosis, as two studies have shown coagulation test 30 and/or abnormalities like protein S deficiency, elevated homocysteinemia and a constitutional elevation of plasma factor VIII coagulant activity ( ). The protease inhibitor treatment may have played a role in increasing the thromboembolic risk. 12
In conclusion, while the proportion of deaths related to HBV end-stage liver disease seems stabilized with effective drugs as part of a cART, there is still an increase in deaths related to HCV end-stage liver disease for which therapeutic options remain limited. The incidence of hepatocellular carcinoma is approximately 2 5 per year in HCV-HIV infected patients with cirrhosis. In the absence of new -% therapeutic options, an exponential burden of deaths from decompensated cirrhosis or hepatocellular carcinoma in HCV-HIV infected subjects is expected in the near future ( , ). To avoid such a scenario, anti-HCV treatment should be widely proposed even in patients 31 32 with cirrhosis provided that they have no decompensation as early HCV viral kinetics predicts 3-month sustained virological response and allows stopping therapy in cases of insufficient viral load decrease. As in HBV infection, regression of liver fibrosis has been observed in HCV-HIV co-infected patients after treatment with pegylated interferon plus ribavirin ( ). Active promotion of alcohol and smoking 33 cessation programs should be widely implemented. Regular screening for hepatocellular carcinoma should be performed in order to detect small unifocal lesions accessible to surgery. Moreover, evaluation of new therapeutic strategies including new drugs (protease inhibitors, polymerase inhibitors) and high doses of ribavirin in patients who failed to respond to a first treatment as recently demonstrated in the PRESCO trial ( ), are urgently needed, and trials must be developed early in HIV-infected patients in parallel to those initiated in HCV 34 mono-infected patients. Lastly, one must remain vigilant about potential new liver complications which may be related to antiretroviral therapy.
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